Cart
sales@molnova.com
Spartalizumab
CAS No. 1935694-88-4
Spartalizumab( —— )
Catalog No. M36809 CAS No. 1935694-88-4
Spartalizumab (PDR001) is a humanized immunoglobulin G4 monoclonal antibody that selectively binds to PD-1 at low concentrations, exhibiting high activity.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 271 | Get Quote |
|
| 5MG | 511 | Get Quote |
|
| 10MG | 871 | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameSpartalizumab
-
NoteResearch use only, not for human use.
-
Brief DescriptionSpartalizumab (PDR001) is a humanized immunoglobulin G4 monoclonal antibody that selectively binds to PD-1 at low concentrations, exhibiting high activity.
-
DescriptionSpartalizumab (PDR001) is a humanized immunoglobulin 4 monoclonal antibody that binds PD-1 with subnanomolar activity and blocks interaction with PD-L1 and PD-L2. Spartalizumab can be used for the research of anaplastic thyroid carcinoma (ATC).
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayImmunology/Inflammation
-
TargetPD-1/PD-L1
-
RecptorPD-1/PD-L1
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1935694-88-4
-
Formula Weight
-
Molecular Formula——
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Jaume Capdevila, et al. PD-1 Blockade in Anaplastic Thyroid Carcinoma. J Clin Oncol. 2020 Aug 10;38(23):2620-2627.?
molnova catalog
related products
-
PD-1/PD-L1-IN-10
PD-1/PD-L1-IN-10 is an orally active?PD-1/PD-L1?inhibitor (IC50?of 2.7 nM) with potent anticancer efficacy.
-
CCC07-01
CCC07-01 (CCC 0701) is a novel alkylating compound that is capable of disrupting expression of PD-1, PD-L1 and CTLA-4 genes with IC50 of 15, 10 and 5 nM in cell-base assays.
-
Nofazinlimab
Nofazinlimab (CS1003) is a human anti-PD-1 IgG4 monoclonal antibody used to study unresectable hepatocellular carcinoma (uHCC) and metastatic colorectal cancer.
